The GiveWell Blog

Our recent visit to Burkina Faso

GiveWell staff recently visited Burkina Faso to meet with staff of one of our top charities, Malaria Consortium’s seasonal malaria chemoprevention (SMC) program, and observe its work. Through its SMC program, Malaria Consortium distributes preventative anti-malarial medication at a time of year when it is needed most.

As I write below, GiveWell donors have directed more than $37 million to Malaria Consortium over the last 18 months at our recommendation. We expect that this will provide preventative treatments to 4.8 million children and avert over 16,000 deaths. We’re so appreciative of the support of our community in enabling this tremendous impact.

We originally sent a version of the following message to supporters of Malaria Consortium’s SMC program in late August. We received positive feedback on this message and decided to share it more broadly on our blog. We plan to publish more information about the 2019 Burkina Faso site visit in the future.

Hello from Burkina Faso!

I’m here on a site visit of Malaria Consortium, one of our recommended charities, to see its malaria prevention program in action.

This visit helped me relate more deeply to the program by getting to know some of the people who run it and some of the people who benefit from it. I wanted to share my experience with you.

Read More

A grant to Evidence Action Beta to prototype, test, and scale promising programs

In July 2018, we recommended a $5.1 million grant to Evidence Action Beta to create a program dedicated to developing potential GiveWell top charities by prototyping, testing, and scaling programs which have the potential to be highly impactful and cost-effective.

This grant was made as part of GiveWell’s Incubation Grants program, which aims to support potential future GiveWell top charities and to help grow the pipeline of organizations we can consider for a recommendation. Funding for Incubation Grants comes from Good Ventures, a large foundation with which we work closely.

Summary

This post will discuss the following:

  • Why Evidence Action Beta is promising. (More)
  • Risks we see with this Incubation Grant. (More)
  • Our plans for following Evidence Action Beta’s work going forward. (More)

Read More